Tags : Monoferric

Pharmacosmos’ Monoferric 1000 mg IV Receives Health Canada Marketing Approval

Shots:  Monoferric is being approved for anaemic adult patients intolerant or unresponsive to iron oral therapy with an expection to reach market by Nov 2018 In 2015, Pharmacosmos signed Canada commercialization rights of Monoferric to Pfizer Canada Monoferric IV has a novel matrix structure of linear isomaltoside chains interspersed with Fe3+ and already being marketed […]Read More